Special Diabetes Program Reauthorization Act of 2023

Bill 118 HR 2550, also known as the Special Diabetes Program Reauthorization Act of 2023, is a piece of legislation that aims to reauthorize funding for the Special Diabetes Program (SDP) for an additional five years. The SDP was originally established in 1997 to support research into type 1 diabetes and to provide funding for type 2 diabetes prevention and treatment programs.

The bill proposes to allocate $150 million per year for the SDP, with $150 million specifically designated for type 1 diabetes research and $150 million for type 2 diabetes prevention and treatment programs. This funding will support research into new treatments and technologies for managing diabetes, as well as programs aimed at preventing the onset of type 2 diabetes through lifestyle interventions and community outreach.

In addition to funding research and prevention programs, the bill also includes provisions to improve access to diabetes care for underserved populations, such as low-income individuals and communities of color. It also calls for increased coordination between federal agencies and stakeholders in the diabetes community to ensure that resources are being used effectively and efficiently. Overall, the Special Diabetes Program Reauthorization Act of 2023 seeks to continue the important work of the SDP in advancing diabetes research and improving outcomes for individuals living with diabetes. By reauthorizing funding for the program, Congress aims to support ongoing efforts to find a cure for diabetes and to reduce the burden of this chronic disease on individuals, families, and the healthcare system.